See our latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
Moderna’s next-gen COVID vaccine notched a higher immune response than its licensed counterpart, passing a phase 3 test.  | Moderna's next-gen COVID vaccine beat its approved counterpart in phase 3, ...
The FDA has authorized Invivyd's Pemgarda™ (pemivibart), indicated for prevention of COVID-19 in adults and adolescents ages 12 and older.
The CEO of the world's biggest vaccine maker, Serum Institute of India, said the company has bolstered its manufacturing ahead of launches over the next few years of shots against diseases like ...
Stock of BioNTech SE (BNTX) is gaining over 5 percent on Monday following the announcement of presentation of clinical data updates regarding its investigational mRNA-based cancer vaccine and ...
In early fall, the federal government recommended an updated vaccine that is targeted against variants that are currently circulating, which are related to XBB, an offshoot of the omicron variant.
thereby reducing BioNTech's vaccine revenues. During the Class Period, as the number of COVID-19 cases began to decline, one variant of the virus, namely, the Omicron XBB.1.5 subvariant, increasingly ...
This paradoxical revelation suggests that incorporating these mutations into new vaccine designs could significantly boost their efficacy, especially against formidable foes like the Omicron variant ...
Meissa Vaccines is putting its portfolio on hold and ... it was highly immunogenic with an outstanding safety profile,” CEO Frank Glavin said in an emailed statement. The nose spray, dubbed ...